In vivo injection of anti-FasL, but not anti-TNF-alpha or anti-TRAIL antibodies, blocked activation-induced cell death of CD8+ T cells, improved type 1 immune responses, and reduced the infection severity as estimated by parasitemia (22, 23). The gene discussed is FASLG; the disease is infection.